XML 58 R44.htm IDEA: XBRL DOCUMENT v3.22.1

Note 11- Collaborative and Other Relationships (Details Textual) $ in Thousands					1 Months Ended		3 Months Ended
	Sep. 15, 2021 USD ($)	Nov. 05, 2019 USD ($)	Sep. 06, 2018 USD ($)	Sep. 30, 2013 USD ($)	Aug. 31, 2020 USD ($)	Jun. 30, 2000 USD ($)	Mar. 31, 2022 USD ($)	Mar. 31, 2021 USD ($)	Mar. 31, 2015 USD ($)
Revenue from Contract with Customer, Including Assessed Tax							$ 49,923	$ 19,059
US Department of Health and Human Services [Member]
Collaborative Agreement Contract Value			$ 34,660
Contract Term (Year)			5 years
US Department of Health and Human Services [Member] | RAPIVAB [Member]
Maximum Number of Products, Doses			50,000
Proceeds from Collaborators							20,782
Torii Pharmaceutical Co. [Member]
Revenue from Contract with Customer, Including Assessed Tax		$ 22,000
Potential Milestone Payments Receivable if Regulatory Approval Before December 31, 2021		$ 15,000
Maximum Customary Reduction on Royalty Rate		50.00%
Royalty Payments Receivable, Expiration Term From First Commercial (Year)		10 years
Torii Pharmaceutical Co. [Member] | Minimum [Member]
Royalty Rate if Maintains Sakigake Designation		20.00%
Torii Pharmaceutical Co. [Member] | Maximum [Member]
Royalty Rate if Maintains Sakigake Designation		40.00%
Base Contract [Member]
Government Contract Receivable									$ 16,265
Additional Development Options [Member]
Government Contract Receivable									22,855
ASPRBARDA Contract [Member]
Government Contract Receivable									$ 39,120
Proceeds from awards for Research and Development Contracts							$ 20,574
AECOM and IRL [Member]
Milestone Payment Minimum						$ 1,400
Milestone Payment Maximum						4,000
Annual License Fee Minimum						150
Annual License Fee Maximum						$ 500
National Institute of Allergy and Infectious Diseases [Member]
Expected Receivable From Awards for Research and Development Contracts	$ 47,315			$ 45,931
Collaborative Agreement Contract, Covenant, Maximum Amount of Funding					$ 43,908
Collaborative Agreement Contract Value					$ 6,326
UAB [Member]
Period of Agreement (Year)							25 years
Renewable Period of Agreement (Year)							5 years

X

- Definition

Represents annual maximum license fee.

+ References

No definition available.

+ Details

Name:	bcrx_AnnualLicenseFeeMaximum
Namespace Prefix:	bcrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Represent minimum annual license fee.

+ References

No definition available.

+ Details

Name:	bcrx_AnnualLicenseFeeMinimum
Namespace Prefix:	bcrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Represents collaborative agreement contract maximum amount if all contract options are exercised, to manufacture and evaluate the safety, efficacy and tolerability of galidesivir.

+ References

No definition available.

+ Details

Name:	bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding
Namespace Prefix:	bcrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Represents collaborative agreement contract value.

+ References

No definition available.

+ Details

Name:	bcrx_CollaborativeAgreementContractValue
Namespace Prefix:	bcrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Period of time between the contract date and its expiration.

+ References

No definition available.

+ Details

Name:	bcrx_ContractTerm
Namespace Prefix:	bcrx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents expected receivable from awards for research and development contracts.

+ References

No definition available.

+ Details

Name:	bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts
Namespace Prefix:	bcrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The maximum percentage of customary reductions allowed on royalty rate.

+ References

No definition available.

+ Details

Name:	bcrx_MaximumCustomaryReductionOnRoyaltyRate
Namespace Prefix:	bcrx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Information on the maximum number of doses of RAPIVAB permitted under the contract.

+ References

No definition available.

+ Details

Name:	bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses
Namespace Prefix:	bcrx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents milestone payment maximum.

+ References

No definition available.

+ Details

Name:	bcrx_MilestonePaymentMaximum
Namespace Prefix:	bcrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Represents milestone payment minimum.

+ References

No definition available.

+ Details

Name:	bcrx_MilestonePaymentMinimum
Namespace Prefix:	bcrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Represents period of agreement.

+ References

No definition available.

+ Details

Name:	bcrx_PeriodOfAgreement
Namespace Prefix:	bcrx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The amount of potential milestone payments receivable if regulatory approval is granted before December 31, 2021.

+ References

No definition available.

+ Details

Name:	bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021
Namespace Prefix:	bcrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Represents proceeds from awards for research and development contracts.

+ References

No definition available.

+ Details

Name:	bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts
Namespace Prefix:	bcrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Represents renewable period of agreement.

+ References

No definition available.

+ Details

Name:	bcrx_RenewablePeriodOfAgreement
Namespace Prefix:	bcrx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The expiration term of the royalty payments from first commercial date.

+ References

No definition available.

+ Details

Name:	bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial
Namespace Prefix:	bcrx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The percent of net sales that the company will receive if berotralstat maintains its Sakigake designation during the PMDA review.

+ References

No definition available.

+ Details

Name:	bcrx_RoyaltyRateIfMaintainsSakigakeDesignation
Namespace Prefix:	bcrx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

The amount of receivables that are derived from government contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 912
-SubTopic 310
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=126938201&loc=d3e55295-109406

+ Details

Name:	us-gaap_GovernmentContractReceivable
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Cash received from collaborators during the current period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585

+ Details

Name:	us-gaap_ProceedsFromCollaborators
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	srt_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=bcrx_RAPIVABMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=bcrx_BaseContractMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=bcrx_AdditionalDevelopmentOptionsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=bcrx_ASPRBARDAContractMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_UABMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: